Antide (Nal-Lys GnRH antagonist) suppression of pituitary-testicular function and sexual behavior in group-living rhesus monkeys.
The ability of a Nal-Lys gonadotropin releasing-hormone antagonist (Antide) to suppress pituitary-testicular function and male sexual behavior was studied in seven group-living adult male rhesus monkeys. Each male received a single 15 mg/kg b.wt. subcutaneous injection of Antide dissolved in equal volumes of propylene glycol and sterile water. Prior to Antide treatment, and at two, four, and eight weeks after Antide, males received an IV bolus of GnRH (50 ng/kg) to assess pituitary and testicular function. For four weeks before and eight weeks after Antide treatment, blood samples and behavioral observations were collected three times weekly in a 74-member heterosexual group. Antide levels increased to more than 150 ng/ml 24 h postinjection and remained above 15 ng/ml for 30 days postinjection. Circulating LH and T were significantly reduced within 24 h following Antide, and remained significantly lower than pretreatment levels in all males for 5 weeks after Antide. T levels rose above 1 ng/ml while Antide levels were still significantly elevated in four males. Both LH and T returned to pretreatment levels by seven weeks post-Antide and then showed a second significant decrease during the eighth study week. Pituitary responsiveness to exogenous GnRH was reduced by Antide and remained below pretreatment levels eight weeks after Antide treatment. Testosterone secretion in response to exogenous GnRH was significantly reduced at two and four weeks post-Antide, but was at pretreatment levels by eight weeks after Antide. Male sexual behavior declined significantly within one week after Antide treatment, almost ceased completely by four weeks after Antide, and returned to pretreatment levels by seven weeks post-Antide.(ABSTRACT TRUNCATED AT 250 WORDS)
Wallen
K
K
Department of Psychology, Emory University, Atlanta, GA 30322.
Eisler
J A
JA
Tannenbaum
P L
PL
Nagell
K M
KM
Mann
D R
DR
D000818:Animals; D003307:Copulation / Q000187:drug effects; D004542:Ejaculation / Q000187:drug effects; D007987:Gonadotropin-Releasing Hormone / Q000037:antagonists & inhibitors*; D007989:Libido / Q000187:drug effects; D007986:Luteinizing Hormone / Q000097:blood; D008253:Macaca mulatta; D008297:Male; D009842:Oligopeptides / Q000493:pharmacokinetics / Q000494:pharmacology*; D010902:Pituitary Gland / Q000187:drug effects*; D012726:Sexual Behavior, Animal / Q000187:drug effects*; D012931:Social Environment; D013737:Testis / Q000187:drug effects*; D013739:Testosterone / Q000097:blood
D009842:Oligopeptides; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone; D007986:Luteinizing Hormone; C057022:iturelix